Kemp Dolliver
Stock Analyst at Brookline Capital
(0.56)
# 3,991
Out of 4,915 analysts
17
Total ratings
38.46%
Success rate
-21.09%
Average return
Main Sectors:
Stocks Rated by Kemp Dolliver
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RADX Radiopharm Theranostics | Initiates: Buy | $18 | $4.71 | +282.17% | 1 | Jul 21, 2025 | |
| LSTA Lisata Therapeutics | Maintains: Buy | $20 → $32 | $2.50 | +1,180.00% | 1 | Jul 15, 2025 | |
| YMAB Y-mAbs Therapeutics | Initiates: Buy | $17 | $4.47 | +280.31% | 1 | Dec 5, 2024 | |
| VRCA Verrica Pharmaceuticals | Downgrades: Hold | n/a | $5.63 | - | 2 | Oct 2, 2024 | |
| IBIO iBio, Inc. | Initiates: Buy | $3.6 | $0.68 | +429.41% | 1 | Jul 22, 2024 | |
| DARE Daré Bioscience | Upgrades: Buy | $36 | $2.40 | +1,400.00% | 2 | May 15, 2024 | |
| OTLK Outlook Therapeutics | Upgrades: Buy | $31 | $1.96 | +1,502.04% | 1 | Jan 25, 2024 | |
| CYCC Cyclacel Pharmaceuticals | Downgrades: Hold | n/a | $11.21 | - | 1 | Dec 19, 2023 | |
| LNTH Lantheus Holdings | Initiates: Buy | $100 | $71.19 | +40.47% | 1 | Nov 30, 2023 | |
| EDSA Edesa Biotech | Maintains: Buy | $57 | $2.25 | +2,433.33% | 2 | Oct 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $25 | $3.39 | +637.46% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $6.89 | +172.13% | 1 | Jan 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $8 | $0.69 | +1,059.25% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5.65 | $1.02 | +453.92% | 1 | Feb 2, 2022 |
Radiopharm Theranostics
Jul 21, 2025
Initiates: Buy
Price Target: $18
Current: $4.71
Upside: +282.17%
Lisata Therapeutics
Jul 15, 2025
Maintains: Buy
Price Target: $20 → $32
Current: $2.50
Upside: +1,180.00%
Y-mAbs Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $17
Current: $4.47
Upside: +280.31%
Verrica Pharmaceuticals
Oct 2, 2024
Downgrades: Hold
Price Target: n/a
Current: $5.63
Upside: -
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $0.68
Upside: +429.41%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $2.40
Upside: +1,400.00%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $1.96
Upside: +1,502.04%
Cyclacel Pharmaceuticals
Dec 19, 2023
Downgrades: Hold
Price Target: n/a
Current: $11.21
Upside: -
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $71.19
Upside: +40.47%
Edesa Biotech
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $2.25
Upside: +2,433.33%
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $3.39
Upside: +637.46%
Jan 13, 2023
Initiates: Buy
Price Target: $19
Current: $6.89
Upside: +172.13%
Oct 21, 2022
Assumes: Buy
Price Target: $8
Current: $0.69
Upside: +1,059.25%
Feb 2, 2022
Initiates: Buy
Price Target: $5.65
Current: $1.02
Upside: +453.92%